State Street
ABOS icon

State Street’s Acumen Pharmaceuticals ABOS Stock Holding History

State Street’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$358K Buy
151,728
+51,550
+51% +$131K ﹤0.01% 3734
2025
Q4 		$211K Sell
100,178
-6,500
-6% -$12.9K ﹤0.01% 3888
2025
Q3 		$182K Hold
106,678
– – ﹤0.01% 3931
2025
Q2 		$124K Sell
106,678
-414,528
-80% -$446K ﹤0.01% 3938
2025
Q1 		$573K Sell
521,206
-4,600
-0.9% -$6.57K ﹤0.01% 3564
2024
Q4 		$904K Buy
525,806
+9,400
+2% +$22.6K ﹤0.01% 3510
2024
Q3 		$1.28M Buy
516,406
+79,841
+18% +$217K ﹤0.01% 3439
2024
Q2 		$1.06M Buy
436,565
+354,787
+434% +$1.13M ﹤0.01% 3466
2024
Q1 		$331K Sell
81,778
-3,300
-4% -$12.4K ﹤0.01% 3750
2023
Q4 		$327K Buy
85,078
+25,300
+42% +$75.1K ﹤0.01% 3755
2023
Q3 		$248K Hold
59,778
– – ﹤0.01% 3869
2023
Q2 		$288K Hold
59,778
– – ﹤0.01% 3889
2023
Q1 		$243K Hold
59,778
– – ﹤0.01% 4003
2022
Q4 		$323K Buy
59,778
+12,400
+26% +$83.3K ﹤0.01% 3923
2022
Q3 		$475K Buy
47,378
+12,900
+37% +$74K ﹤0.01% 3799
2022
Q2 		$162K Sell
34,478
-150,380
-81% -$565K ﹤0.01% 4299
2022
Q1 		$723K Buy
184,858
+73,495
+66% +$400K ﹤0.01% 3908
2021
Q4 		$753K Buy
111,363
+11,588
+12% +$127K ﹤0.01% 3880
2021
Q3 		$1.48M Buy
+99,775
New +$1.66M ﹤0.01% 3696

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

State Street's ABOS Position: Q1 2026 in Review

State Street increased its Acumen Pharmaceuticals (ABOS) stake by 51% in Q1 2026, buying an estimated $131K and bringing the position to 151,728 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

State Street first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.48M in Q3 2021. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • State Street held 151,728 shares of Acumen Pharmaceuticals worth $358K as of Q1 2026.
  • State Street bought 51,550 Acumen Pharmaceuticals shares in Q1 2026, an estimated $131K.
  • Acumen Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3734 holding.
  • State Street first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • State Street's Acumen Pharmaceuticals position peaked at $1.48M in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.